Investor Watch | Psilocybin Innovation Takes Off – Startups, Trials, and Policy Breakthroughs

“The Magic Mushroom” – or its key ingredient, Psilocybin – appears to be out in the lead in the modern wave of psychedelic research. Alongside the high-profile Phase II trial results from Compass Pathways (CMPS, profiled previously on TrialSite News), a handful of other early studies are progressing, or close to starting: Usona Institute, Filament Health, Numinus (NUMI), Diamond Therapeutics, TheraPsil.